Skip to content

Study · Animal study (in vivo) · rat · 2017

4 results

Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.

Belosic Halle Z, Vlainic J, Drmic D, Strinic D, Luetic K, Sucic M, Medvidovic-Grubisic M, Pavelic Turudic T, Petrovic I, Seiwerth S, Sikiric P

Inflammopharmacology17 May 2017Cited by 41 (Europe PMC)

PMID28516373 (opens in a new tab)DOI10.1007/s10787-017-0358-8 (opens in a new tab)PepBankPUB-28516373
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, BPC‑157 rescued, dose-dependently, the decreased sphincter pressure caused by dopamine antagonists, L-NAME and L-arginine.

    In plain wordsIn rats, BPC‑157 restored lowered pressure in two gut valves caused by several drugs, in a dose-dependent way.

    Peptide
    BPC-157
    Outcome
    IncreaseLower oesophageal and pyloric sphincter pressure after dopamine antagonists, L-NAME and L-arginine
    Study

    ratn: not reported in source

    dopamine antagonist or L-NAME induced low sphincter pressure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    As a common effect, this decreased pressure was rescued, dose-dependently, by BPC 157 (10 µg, 10 ng) (also note that L-arginine and L-NAME given together antagonized each other's responses).
    1 context sentence
    Summary · context
    Therefore, in a 1-week study, we examined the pressures within the lower oesophageal and the pyloric sphincters in rats [assessed manometrically (cm H2O)] after dopamine neuroleptics/prokinetics, L-NAME, L-arginine and stable gastric pentadecapeptide BPC 157 were administered alone and/or in combination.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given haloperidol or domperidone with L-NAME or L-arginine, adding BPC‑157 moved sphincter pressures towards a stronger beneficial effect, close to normal values.

    In plain wordsIn rats, adding BPC‑157 moved gut valve pressures close to normal values.

    Peptide
    BPC-157
    Outcome
    IncreaseSphincter pressure with haloperidol or domperidone combined with L-NAME or L-arginine
    Study

    ratn: not reported in source

    dopamine antagonist or L-NAME induced low sphincter pressure
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    All these effects were further reversed towards a stronger beneficial effect, close to normal pressure values, by the addition of BPC 157.
    1 context sentence
    Summary · context
    Therefore, in a 1-week study, we examined the pressures within the lower oesophageal and the pyloric sphincters in rats [assessed manometrically (cm H2O)] after dopamine neuroleptics/prokinetics, L-NAME, L-arginine and stable gastric pentadecapeptide BPC 157 were administered alone and/or in combination.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats given haloperidol, BPC‑157 counteracted the increase in NO levels.

    In plain wordsIn rats given haloperidol, BPC‑157 counteracted the rise in nitric oxide levels.

    Peptide
    BPC-157
    Outcome
    DecreaseNO levels after haloperidol (sphincters, plasma, brain)
    Study

    ratn: not reported in source

    dopamine antagonist or L-NAME induced low sphincter pressure
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Haloperidol increased NO levels (in both sphincters, the plasma and brain), consistently producing increased TBARS levels in the plasma, sphincters and brain tissues. These effects were all counteracted by BPC 157 administration.
    1 context sentence
    Summary · context
    Therefore, in a 1-week study, we examined the pressures within the lower oesophageal and the pyloric sphincters in rats [assessed manometrically (cm H2O)] after dopamine neuroleptics/prokinetics, L-NAME, L-arginine and stable gastric pentadecapeptide BPC 157 were administered alone and/or in combination.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In rats given haloperidol, BPC‑157 counteracted the increase in TBARS levels.

    In plain wordsIn rats given haloperidol, BPC‑157 counteracted the rise in an oxidative stress marker.

    Peptide
    BPC-157
    Outcome
    DecreaseTBARS levels after haloperidol (plasma, sphincters, brain)
    Study

    ratn: not reported in source

    dopamine antagonist or L-NAME induced low sphincter pressure
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).

    Source sentences

    Summary
    Haloperidol increased NO levels (in both sphincters, the plasma and brain), consistently producing increased TBARS levels in the plasma, sphincters and brain tissues. These effects were all counteracted by BPC 157 administration.
    1 context sentence
    Summary · context
    Therefore, in a 1-week study, we examined the pressures within the lower oesophageal and the pyloric sphincters in rats [assessed manometrically (cm H2O)] after dopamine neuroleptics/prokinetics, L-NAME, L-arginine and stable gastric pentadecapeptide BPC 157 were administered alone and/or in combination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.